M
514.06
-42.16 (-7.58%)
| Previous Close | 556.22 |
| Open | 552.50 |
| Volume | 703,253 |
| Avg. Volume (3M) | 351,077 |
| Market Cap | 11,675,032,576 |
| Price / Sales | 14.85 |
| Price / Book | 18.00 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Paulson & Co. Inc. | 30 Sep 2025 | 1,907,523 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 900.00 (Piper Sandler, 75.08%) | Buy |
| Median | 630.00 (22.55%) | |
| Low | 445.00 (B of A Securities, -13.43%) | Hold |
| Average | 629.88 (22.53%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 526.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 19 Dec 2025 | 900.00 (75.08%) | Buy | 591.02 |
| B. Riley Securities | 11 Dec 2025 | 670.00 (30.33%) | Buy | 571.33 |
| HC Wainwright & Co. | 21 Nov 2025 | 620.00 (20.61%) | Buy | 547.96 |
| 11 Nov 2025 | 568.00 (10.49%) | Buy | 541.50 | |
| Oppenheimer | 20 Nov 2025 | 650.00 (26.44%) | Buy | 542.12 |
| Truist Securities | 19 Nov 2025 | 640.00 (24.50%) | Buy | 555.60 |
| Canaccord Genuity | 13 Nov 2025 | 587.00 (14.19%) | Buy | 514.93 |
| Citizens | 05 Nov 2025 | 527.00 (2.52%) | Buy | 475.87 |
| B of A Securities | 03 Nov 2025 | 445.00 (-13.43%) | Hold | 412.35 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |